Published September 1997
by Blackwell Science .
Written in English
|Contributions||Stephen T. Holgate (Editor), Sven-Erik Dahlen (Editor)|
|The Physical Object|
|Number of Pages||336|
R. A. Lewis, J. M. Drazen, K. F. Austen, D. A. Clark, and E. J. Corey, Identification of the C(6)-S-conjugate of leukotriene with cysteine as a naturally occurring slow-reacting substance of anaphylaxis (SRS-A): importance of the cis-geometry for biological activity, Biochem. Biophys. Res. Commun., – (b). PubMed CrossRef Cited by: 9. Thus SRS-A is a mixture of the cysteine-containing leukotrienes, that is, the parent compound LTC 4 and the metabolites LTD 4 and LTE 4. The relative proportion of these leukotrienes depends on the procedure used to prepare the SRS-A. The hypothesized role of the unstable epoxide intermediate (LTA 4) as precursor of SRS (LTC 4) was confirmed (6, 45).Cited by: Description. The Leukotrienes, Chemistry and Biology discusses the significant scientific progress of leukotrienes, from the discovery of slow-reacting substance to the chemical identification of a mixture of leukotrienes. Composed of 11 chapters, the book Book Edition: 1. A tilird and minor component, ll-frans-LTC, was also detected. Perspectivts Previous work has suggested that SRS-A is an important mediator of symptoms in asthma and other immiat hypersensitivity reactions. The work described in this review has led 10 struc- ture determination of the compounds (leukotrienes C and D) responsible for SRS-A activity.
SRS-A leukotrienes decrease the activity of human respiratory cilia. Bisgaard H, Pedersen M. We have studied the effects of the slow reacting substance of anaphylaxis (SRS-A) constituents leukotrienes (LT) C4 and D4 on the ciliary activity of human respiratory cells. The ciliary beat frequency on human nasal cells harvested by cell scraping from the inferior turbinate was measured in a blind design by a . The discovery that the slow reacting substance of anaphylaxis (SRS-A) was a mixture of leukotrienes released from mast cells and basophils sparked the search for antagonists of leukotriene receptors. Independent medicinal chemistry strategies were employed to identify both of the antagonists in clinical use (Table ). Peptidoleukotrienes: also called the cysteinyl leukotrienes, LTC 4, LTD 4, LTE 4, and LTF 4 constitute this group of eicosanoids because of the presence of amino acids Slow-reacting substance of anaphylaxis (SRS-A): consists of the leukotrienes LTC 4, LTD 4, and LTE 4, secreted by mast cells during anaphylactic reaction, induces slow. The cysteinyl leukotrienes make up the slow-reacting substance of anaphylaxis (SRS-A). LTF 4, like LTD 4, is a metabolite of LTC 4, but, unlike LTD 4, which lacks the glutamic residue of glutathione, LTF 4 lacks the glycine residue of glutathione.
leukotriene synthesis a new class of biologically active compounds including srs a medicine health science books amazoncom A New Class Of Leukotriene Biosynthesis Inhibitors The the full biological profile has been detailed elsewhere but it is relevant to note the important increase in potency in the human new class of leukotriene biosynthesis inhibitors ocx 1 l 1 enantiomer. Synthesis and metabolism of leukotrienes -- pt. 2. Cardiovascular pharmacology of the leukotrienes -- pt. 3. Leukotriene receptors and new antagonists -- pt. 4. Leukotrienes and the immune system -- pt. 5. Pulmonary physiology and pharmacology of the leukotrienes -- pt. 6. Leukotrienes and human pathophysiology -- pt. 7. slow reacting substance (SRS and SRS-A). The peptidolipid leukotrienes are potent bronchoconstrictors and enhance mucus production in the lungs. Furthermore, they constrict coronary arteries and have a negative inotropic effect. They probably play an important role in asthma and anaphylaxis. LTB4 and the peptidolipid. in the two decades since the elusive slow reacting substance of anaphylaxis srs a was identified as a product of the action of the 5 lipoxygenase enzyme on arachidonic acid it has been well established that the leukotrienes are key mediators of both aliergy and inflammation their release by Leukotrienes New Concepts And Targets For Therapy